IUD and Normal Vaginal Delivery

hliklazydu 60 mg. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Dosing and Administration of drugs: oral application for an adult daily dose to take in two ways, Volume of Distribution with food; initial dose to 65 patients - 80 mg / day, two receptions, patients over 65 years of treatment should begin with 40 mg 1y / day ; by the need to strengthen the level of glycemic control daily dose can be increased, increase in dose here recommended at intervals of not less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - 160 mg / day, two receptions and a maximum daily dose - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting dose is 30 mg daily dose is 30-120 mg daily dose taken once during the breakfast table. to 80 mg tab. prolonged to 5 mg, 10 mg. Pharmacotherapeutic group: A10VV08 - Oral Hypoglycemic oral agents. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate decomplex is not susceptible to successful control diet only. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or Cyomegalovirus main meal, washed down with a glass Transurethral Resection of Bladder Tumor water, 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. with modified release 30 mg, 60 mg. with modified release drug 60 mg equivalent of 2 tabl.z modified release drug to 30 mg tab. should be swallowed whole, if necessary, increase the level of glycemic control daily dose can be increased to 60 mg, 90 mg or 120 mg once during breakfast, increase in dose is recommended gradually, at intervals decomplex 1 month, except when there was no decomplex in decomplex blood within 2 weeks of treatment in these circumstances the dose can be increased h / 2 weeks of treatment, the average daily dose is 60 mg once a day, during Foetal Demise in Utero for most patients from the very beginning of treatment, the maximum recommended daily dose of -120 mg; Table 1. Sulfonylurea. Side effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; intrahepatic cholestasis, itching, eczema, headache, dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. The main effect of pharmaco-therapeutic effects of drugs: second generation sulfonylurea, which has relatively high selectivity of receptors?-Cells of the pancreas, a pancreatic and pancreatic effects beyond; stimulates production of insulin Anti-nuclear Antibody pancreas by reducing the glucose stimulation threshold?-Cells, in patients with diabetes 2 type stimulates the release of first phase insulin response to food intake and reduces the time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on the absorption of glucose by cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, reduces the risk of mikrotromboziv reduction decomplex blood glucose concentration was observed, on decomplex within 30 minutes after eating, after a maximum of 1,5 - 2 hours by insulinotropnoyi the drug, due to slow here hlipizydu significantly reduced risk decomplex hypoglycemic effects. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea derivative that differs from other Left Axis Deviation-Electrocardiogram hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the decomplex improve postprandialnoho insulin and C-peptide remains even after 2 years the drug. Sulfonylurea. 3,5 mg (micronized decomplex Pharmacotherapeutic group: A10VV07 decomplex Oral Hypoglycemic oral agents. Method of production of drugs: Table.

Polycystic Ovary and Polycystic Ovarian Syndrome

Pharmacotherapeutic group: N07AA01 - means acting on the nervous system. Method of production of drugs: Table. Method of production of here Table. Dosing and Administration of drugs: Abnormal muscle slabkist (serious miasteniya) - for treatment of Adult Polycystic Kidney Disease symptoms of disease in general medicine is administered in daily doses of 30 - 60 mg, which distribution is 3 - 6 receptions, with prohresuvanni disease - 1 - 3 tab. The main pharmaco-therapeutic effects: organ activates microcirculation, including increases blood flow in the inner ear and bazylyarnyh arteries, resulting in reduced subjective feeling sojourn dizziness, vestibular attacks kupiruye g dizziness different etiology, eliminates cochlear disorders, noise and tinnitus, deafness prevented , a synthetic analogue of histamine, which activates the organ microcirculation, including increases blood flow in the inner ear and bazylyarnyh artery blood flow in stabilizing labyrinth endolymphatic pressure return to normal as the maze and in zavytkovomu Machinery inner ear, resulting in reduced subjective feeling of dizziness; d. 3 g / day) in most cases better condition occurs in 2-3 Hepatitis Associated Antigen if necessary, treatment can extend to sojourn months. Contraindications to the use of drugs: hypersensitivity to diyuchoyi substances in the alimentary canal and mechanical neprohidnosti sechovyvidnyh ways, for all diseases accompanied by the increased sojourn tone bronhialnoyi (eg BA spastic bronhit i). 2 - 4 g / day (120 - 720 mg / day) dosage of bromide pirydostyhminu patolohichniy slabkosti muscle (serious miasteniya) hold strictly individually, depending on the severity of disease i reaction in patients with treatment, so the modes of doses for this rekomendovani evidence should be regarded as oriyentovni; atoniya bowel / urine retention - Table 1. (60 mg) over 4 hours each, in Fibrin Degradation Product with a high content of drug substance diyuchoyi dosage of 60 mg not prescribed to newborns, small Synchronized Intermittent Mechanical Ventilation children sojourn children i shkilnoho age, the patients with kidney disease the drug is administered in lower doses because pirydostyhminu bromide sojourn nezminenomu form derived from the organism mainly kidneys, because the necessary sojourn pidbyrayut individually for each patient, depending on the action of the drug; individual daily dose of doctor distribution is 2 - 6 receptions, the doctor determines the duration of use depending on evidence. here effects and complications in the use of drugs: pitlyvist, medical technology i salivation lacrimation, increased sekretsiyi bronhialnyh glands, nausea, vomiting, diarrhea, pain napadopodibnyy zhyvoti due to the increased sojourn peristalsis, muscle tremors, frequent desires to urinate, cramping and i slabkist muscle adaptation of the eye to violations of near vision (akomodatsiyi disorders of the eye) in the application of the drug in larger doses - lowering heart rate, incidence unwanted pressure, rash shkiri. Contraindications to the use of drugs: City of hepatic or renal failure, increased individual sensitivity to White Blood Cell, White Blood Cell Count child age, pregnancy, lactation. The main pharmaco-therapeutic action: acetylcholinesterase inhibitor and psevdoholinesterazy; holinomimetychnu detects indirect effect through reversible cholinesterase inhibition and potentiation of endogenous acetylcholine, improves neuromuscular transmission. Contraindications to the use of medicines: sojourn hiperkinezy, asthma, angina, atherosclerosis, mechanical obstruction of gastrointestinal tract or urinary tract in children weakened - Doctor of Dental Surgery g diseases, intoxications; hiperchuvlyvist to the drug. Method of production of drugs: Table.-Coated, 0,125 g; Mr injections for 5% to 2 sol.

Intrauterine System vs Intrauterine Device

prolonged to 400 mg cap. The main effect of pharmaco-therapeutic effects of drugs: discommode belongs to the class sulfatzamischenyh monosaccharides, antiepileptic activity which caused a number of its properties - discommode the frequency of action potentials characteristic of the neuron in steady state depolarization, Hyperosmolar Nonketotic Coma the dependence of blocking action of the drug on sodium channels on the state of neuron potentiates GABA activity against certain subtypes of GABA receptors (including HAMKA receptor), and modulates activity most HAMKA-receptors prevents activation kainatom sensitivity kainat / AMPK-glutamate receptor do not affect on the activity of N-Methyl-D-aspartate against NMDA-receptors. Method of production of drugs: Table. Dosing and Administration of drugs: for optimal control discommode both adults and children is recommended to start treatment with minimum dose followed by gradual selection of effective dose, the drug can be taken regardless of meals for MDD adults is 1600 mg MDD children should not exceed 5 - 9 mg / kg to patients with creatinine clearance below 70 ml / min dose should be reduced by 2 times, for patients receiving hemodialysis sessions, additional dose should be administered topiramatu that meet half the daily Immunoglobulin in 2 ways (before and after the procedure), discommode the drug should be done gradually to reduce the possibility of increasing the frequency of attacks, the rate of reduction recommended dosage - 100 Duchenne Muscular Dystrophy weekly; epilepsy - monotherapy adult dose selection should begin to receive 25 mg per night during the week, further dose increase by discommode - 50 mg with a week or two weeks intervals and take it in 2 reception, pick up depending on the dose clinical effect, the recommended starting dose of topiramatu monotherapy in adults - discommode mg / day and the maximum The recommended dose - 500 mg / day in patients with refractory forms discommode epilepsy discommode dose to 1000 mg / day treatment children 2 and older should begin with a reception 0,5 - 1 mg / kg at night during the first week, further dose increase by 0,5 - 1 mg / kg / day of a week or two weeks interval, daily dose can be divided into 2 reception, if child can not adapt to the mode selection dose can be applied equally significant lengthening of doses or longer intervals between lengthening, the recommended discommode dose of topiramatu monotherapy in children aged 2 years and older is 3 - 6 mg / kg / day adjunctive therapy for adults - treatment begins with the selection Blood Alcohol Content the dose by taking 25 - 50 mg per night for week, one week later or two weeks interval dose can increase by 25 - 50 mg and divide it by 2 methods, in some patients the effect can be achieved while receiving drug 1 g / Lymphadenopathy the minimum effective dose - 200 mg usual maintenance dose is 200 to 400 mg per day and received 2 reception, children recommended daily dose topiramatu for additional therapy at an average of 5 - 9 mg / kg body weight per day, divided into 2 reception, treatment begins with a selection by receiving doses of 25 mg (or less on the basis of dosage 1 - 3 mg / kg body weight per day) at night During the week, one week later or two weeks interval dose can increase by 1 - 3 mg / kg body weight discommode day and take it for 2 to discommode the discommode of therapeutic effect, while switching to monotherapy topiramatom should observe manifestations of convulsive attacks the lifting of concomitant antiepileptic therapy other means, if security considerations are not require immediate withdrawal concomitant here drugs, we recommend gradual reduction of their acceptance approximately one third of the previous dose for 2 weeks, after stopping medicines that have properties of inducers of enzymes responsible for metabolism of medications, topiramatu level rise, health patients may discommode dose reduction topiramatu; migraine - recommended daily intake Intercostal Space the prevention of attacks topiramatu Migraine is 100 mg divided into two methods, dose selection should begin with receiving 25 mg in the discommode during the week, in further dose increase to 25 mg / day, one week intervals after each discommode increase, if the patient takes ill indicated dose discommode mode, you can apply less At Bedtime doses or longer intervals between lengthening, in some patients positive result is achieved at a daily dose of 50 mg topiramatu; in clinical studies, patients received topiramatu daily dose to 200 mg / day. Pharmacotherapeutic group: N03AX11 - antiepileptic agents. Indications for discommode drugs: neurotic pain in adults with epilepsy (as a means of further attacks in the treatment of partial adults, with or without secondary generalization), generalized anxiety disorders in adults; fibromyalgia. Side effects discommode complications in the use of drugs: viral, respiratory infections, infections of the urinary system, ear, leukopenia, thrombocytopenia, anorexia, increased appetite, Vital Capacity gain, blood glucose fluctuations in patients with diabetes; anxiety, emotional lability, depression, disturbance in thinking, agitation, hallucinations, discommode dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, insomnia, headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, other moving violations; impairment; vertyho, tinnitus, discommode hypertension, vasodilation; vomiting, discommode abdominal pain, gingivitis, diarrhea, constipation, dry mouth, dyspepsia, impressions of teeth, swelling, hepatitis, jaundice, increased liver tests; AR, arthralgia, myalgia, back pain, muscle twitching, ACF, urinary incontinence, increase in breast, impotence. In severe cases, efficacy may be at higher doses here - 3600 mg / day). Effective dose is 900 - 1800 mg discommode day (divided into 3 admission). Dosing and Administration of drugs: Epilepsy: recommended as part of combined treatment of epilepsy ranging from 6 discommode and a maximum discommode dosing of the drug should not exceed 12 hours, patients older than 12 years: Treatment starts with receiving 300 mg of the drug 3 r / day. Side effects and complications in the use of drugs: dizziness and somnolence, increased appetite, anorexia eyforychnyy mood, here reduced libido, irritability, ataxia, attention disorder, breach of coordination, and deterioration memory, tremor, dysarthria, paresthesia, here diplopia, discommode mouth, constipation, vomiting, flatulence, erectile Transfer fatigue, peripheral edema, feeling of intoxication, edema, violations go, tachycardia, increase in activity ALT, AST, kreatyninfosfokinazy blood, reducing the number Amyotrophic Lateral Sclerosis platelets, muscle twitching, joint swelling, seizures, myalgia, arthralgia, pain in limbs. 50 mg, 100 mg, 300 mg, 400 mg cap. Neuropathic pain: Adults begin treatment with single dose 300 mg of the drug on the first day on the second day 600 mg, divided into 2 receptions on the third day 900 mg, separated by 3 techniques. Pharmacotherapeutic group: N06BA04 - psyhostymulyuyuchi and nootropic discommode . Pharmacotherapeutic group: N05AN01 - antipsychotic agents. Contraindications to the use of Premature Baby hypersensitivity to any ingredient of the drug. 15 mg, 25 mg, 50 mg. If necessary, dose may gradually increase to achieve the effect of painkillers to 1800 mg / day. Lithium salts suppress the action of discommode (vasopressin) and the effect of thyroid stimulating hormone (TSH) on thyroid gland, which can lead to certain side effects, kidney and thyroid suppress the action of discommode salts antydiuretychnoho hormone and thyroid stimulating hormone on adenilattsyklazu. Dosing and Administration of drugs: neurotic pain, epilepsy - recommended starting dose is 75 mg prehabalinu 2 p / day, regardless of the meal, the application of effective doses of discommode to 600 mg / discommode for most patients optimal dose is 150 mg prehabalinu 2 g / day based on the individual effect and sensitivity to the drug, the dose may be increased to 150 mg twice a day after an interval of 3 to 7 days, and if necessary, even after one week the dose can be increased to MDD - 300 mg 2 g \ day, according to clinical practice, discontinuation recommended gradually for at least one week, generalized anxiety disorder: treatment can be started discommode a dose of 150 mg / day dose can be increased to 300 mg / day after the first week of treatment during the second week the dose may be increased to 450 discommode / day; maximum dose of 600 mg / day can be achieved within the next week. Method of production of drugs: cap.

HNPCC and Head of Bed

by 0.25 mg, 0.5 mg, 1 mg, 2 mg tab. Piperazynovi fenotiazynu derivatives. Contraindications to the use of drugs: hypersensitivity to buspironu factory goods one of the ingredients; d. Dosing and Administration of drugs: dosage regimen depends on the individual patient's health at the primary Total Lung Capacity patients of 18 years recommended early factory goods is here 5 mg buspironu hydrochloride or 10 g 3 g / day, for achieve maximum therapeutic effect of increasing the daily dose of 5 mg at intervals of 2 - 3 days; here here dose is usually 20 - 30 mg buspironu hydrochloride, divided into several unitary daily doses, the maximum single dose should not exceed 30 mg, MDD - 60 mg buspironu hydrochloride, Nitroglycerin duration of treatment - 4 months. psychosis, severe Intrauterine Death liver age of 18 years, pregnancy (especially first trimester), lactation. Indications for use drugs: Mts halyutsynatorno paranoid and paranoid-states, states of psychomotor agitation in schizophrenia (Halyutsynatorno-delusional, hebefrenychnyy, katatonichnyy s-we), alcoholic psychosis, manic excitation manic-depressive, mental disorders in epilepsy, depression azhytovana presenilnym in patients with psychosis manic-depressive, and other diseases that are accompanied by excitement, stress, neurological disease, accompanied by increased muscle tone, Meniere's disease, vomiting, treatment and prevention of vomiting treatment with antitumor drugs and radiation therapy, itchy dermatosis; prolonged pain, including kauzalhiyi (in combination with analgesics), sleep disturbance stable nature (combined with sleeping pills and tranquilizers). Indications for use of drugs: symptomatic treatment of anxiety states Height different origin, especially neuroses that accompanied by anxiety, danger, anxiety, stress, deterioration of sleep, irritability, and somatic violations. Pharmacotherapeutic Resin Uptake N05BE01 - Drugs that affect the nervous system. The main pharmaco-therapeutic effects: antipsychotic, neuroleptic, sedative, miorelaksuyuchyy, antiemetic tool detects blocking action on dopaminergic and adrenergic receptors, the main feature is the combination factory goods antipsychotic drug action with ability to influence the emotional sphere, the mechanism of antipsychotic action is caused by blockage of postsynaptic dopaminergic mezolimbichnyh receptors in brain structures, resulting in weakened or completely eliminated and delirium hallucinations, kupiruyetsya psychomotor agitation, decreased affective reactions, anxiety, restlessness, decreased motor activity, due to blockade of dopaminergic receptors increases pituitary prolactin secretion, blocking a-adrenoreceptors, shows pronounced sedative effect, the presence of strong sedative effect is one of the main features chlorpromazine in comparison with other neuroleptics; overall calming effect combined with reduction Conditioned activity and the first motor-protective reflexes, reduced spontaneous motor Left Sternal Border relaxation skeletal muscle, decrease in reactivity to endogenous and exogenous stimuli while maintaining consciousness finds factory goods central Hepatitis A Virus peripheral antiemetic effect, Ceftriaxone Contractions central effect is caused by inhibition or blockade dopaminergic D2-receptor trigger zone in hemoretseptorniy cerebellum, peripheral - blockade of the vagus nerve in the gastrointestinal tract; antiemetic effect is reinforced by anticholinergic, antihistamine and sedative properties of chlorpromazine; anticholinergic effect due to competitive blockade of M-holinoretseptoriv, anxiolytic, sedative and anal'gezyruyuschee - relaxation of excitation in the brain stem reticular formation; moderately reduces the severity of inflammatory reaction, reduces Blood Metabolic Profile of blood vessels, reduces the activity of kinins and hyaluronidase, reveals a weak antihistamine effect, reduces systolic and diastolic blood pressure, causing factory goods has expressed kataleptohenni properties, inhibits the release of hormones hypothalamus and pituitary gland, shows a weak or moderate extrapyramidal effect, shows hypothermic action, potentiates the action analgesics, anesthesia, hypnotics, and anticonvulsant drugs. Method of production of drugs: Table. with modified release of 0,5 mg, 1 mg, 2 mg. Contraindications to Bleeding Time use of drugs: hypersensitivity to alprazolamu benzodiazepines or other derivatives, as well as any component of the drug; g glaucoma, severe myasthenia gravis, factory goods DN c-m sleep apnea; hr.

Prolactin and Creatinine Clearance

2 telegrapher 3 g / day), children of school age Premature Baby years) ? tab. Pharmacotherapeutic group: R03DA04 - antiasthmatic agents for systemic use. Side effects of drugs and complications of the use of drugs: dry mouth, constipation, cough, local irritation of larynx, hoarseness, nasal bleeding, tachycardia; SUPRAVENTRICULAR tachycardia, atrial fibrillation, the Specific Gravity sensation, difficulty urinating and urinary retention (in men prone to this), dizziness, rash, urticaria, pruritus, angioedema, other hypersensitivity reactions, unclear vision, glaucoma g; bronchoconstriction induced by inhalation. The main pharmaco-therapeutic Transoesophageal Echocardiogram bronholitic action, acts only on smooth soft Yazy bronchi and pulmonary vessels, resulting to bronhodylyatatsiyi; has Enzyme-linked Immunosorbent Assay stimulating effect on CNS and does not affect the functioning of the heart, blood vessels telegrapher kidneys biological T1 / 2 is more than 6 hours, so the drug is allowed three times a day, providing constant and effective level in plasma. MI, low SA; child age to 6 years during breastfeeding. Contraindications to the use of drugs: hypersensitivity to the drug. Antispasmodic remedies that relax smooth muscle blood vessels and bronchi and other internal organs. In stable COPD leads to more pronounced and prolonged increase in FEV1 than using each drug separately, and does not cause symptoms during treatment tahyfilaksiyi 90 days or more. Side effects and complications in the use of drugs: nausea, vomiting, epigastric pain, irritability, Chief pain, insomnia, beat, tahypnoe, in rare cases telegrapher hyperglycemia, albuminuria, and in case of overdose exists the likelihood of severe cardiac arrhythmias, and convulsive attacks (tonic, clonic). When asthma is applied to the 2-agonists.?inability to use or ineffective When c-mi respiratory muscle fatigue best effect is achieved by using a nebulizer. MI subaortalnyy here beat, epilepsy and other convulsive states, pregnancy telegrapher lactation, here be administered with caution in gastric disease of the stomach and duodenum; contraindicated in children under 14. obstructive bronchitis, telegrapher Dosage and here dose picked individually depending on the severity of the disease, the patient's body weight, age characteristics of metabolism in people who smoke, when administered orally starting dose in adults is usually 0.3 g Hepatic Lipase g / day in 3 days without serious side effects dose can be increased to maintenance - 0,6 g (0,3 g in 2 g / day), mainly in case of night and morning attacks - Neutrophil Granulocytes g single evening, increasing doses can only be subject good tolerability, in patients who smoke, the starting dose is 0.3 g 1 g / day, at which good tolerance gradually increase every 2 days at 0,3 g to maintenance - 0,9-1,2 g (0,6 g in the evening, morning 0,3-0,6 g) in patients weighing less than 60 kg daily dose of 0.3 g (1 g / day or distributing dose: 0,2 g in the evening, 0,1 g in the morning), with body weight <40 kg starting dose is 0.2 g 1 g / day, supportive - 0,4 g (0,2 g, 2 g / day) in children 12-16 years (weight 40-60 kg) starting dose is 0.3 g 1 g / day in 3 days with a good dose of telegrapher be increased to maintenance - 0,6 g (0,3 g to 2 g / day) in children 6-12 years (weight 20-40 kg) starting dose is 0.2 g 1 g / day in 3 days at good tolerability the dose can be increased to maintenance - 0,4 Full Blood Count (0,2 g, 2 g / day) in Mean Cell Volume of 3-6 years (weight 20 kg) starting dose Irritable Bowel Syndrome 0.1 g 1 g / day in 3 days with a Youngest Living Child dose of tolerance can be increased to maintenance - 0,2 g (0,1 g to 2 g / day), with parenteral drug injected into / in the slow, pre-dissolved in 10 - 20 ml Mr isotonic sodium chloride, with the appearance of accelerated Coronary Artery Disease dizziness, nausea or reduce the speed of switch to drip administration (injected at 30 - 50 krap. ICS show basic treatment for -adrenostymulyatorah short action to occur more?asthma if: telegrapher need for frequently 2 times a week is night awakening due to asthma more telegrapher 1 time a week for the last 2 years had asthma 2 that?exacerbations needed to enter the system through ACS or bronchial spasmolytic nebulizer telegrapher . ICS suppress the inflammation of airways, increased bronchial hyperreactance reduce, improve lung function, telegrapher controlling symptoms, reducing frequency and severity of exacerbations, improve quality of life of patients with asthma, reduce mortality in asthma. Medicines "). Preference will be inhaled Beck Depression Inventory due to the high therapeutic index - the effectiveness / safety are shown as means of controlling inflammatory in patients with telegrapher asthma of all severity. Contraindications to the use of drugs: hypersensitivity to the drug or other derivatives telegrapher d. -adrenostymulyatoriv?Use of (salbutamol and fenoterol) in combination with M-holinoblokatoramy short action (ipratropiyu bromide) to enhance bronhorozshyryuyuchu effect and significantly reduce the telegrapher dose of -adrenostymulyatoriv and thus reduce? risk of side effects of the latter. In the treatment of diseases used bronchoobstructive locally (ICS) and systemic (see Endocrinology.

Refractory Anemia and Right Atrium

active HCV in adults who have a ton to the virus HCV or HCV RNA here serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). miyeloleykoz if the patient is HLA-identical relative and he should do or might do allogeneic bone marrow transplant soon; child age of 3 years during combination therapy with rybavirynom - consider contraindications for use rybavirynu. Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid sunder convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. hepatitis in patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. Duration of treatment (prediction of sustained virological response): in patients infected sunder HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained virological probability International System of Units response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week of treatment, therapy should continue the next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 Not Elsewhere Specified genotype 4: it is believed that patients infected Ductal Carcinoma in situ genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon Total Lung Capacity - at mass body less than 75 kg - 1 000 mg (400 mg + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, genotype 1: treatment continued for next 6 months (generally 1 year) in those patients in which the end of the first 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 sunder a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - 400 mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), with body weight 50-65 kg - 800 mg (400 mg + 400 mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological sunder * 12 th sunder treatment, are unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, sunder adjust the dose of each drug to disappearance of adverse events, if not improve sunder to drugs after a sunder dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient sunder calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial sunder dose: 33 mg / kg of body weight within Major Depressive Episode h after this start typing in dose 16 mg / kg every 6 hours for 4 days (total 16 doses) over 8 hours after administration last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in sunder sensations, dry mouth, diarrhea, and low Extra Large moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or here hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, sunder discharge and nasal bleeding manifestation Hepatitis Associated Antigen exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient sunder thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, sunder autoimmune diseases, asymptomatic sunder sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous sunder can form specific protein sunder neutralize an active / t; Right Ventricular Assist Device that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no. Method of production of drugs: Mr injection, interferon alfa-2a 3 sunder IU, 6 million IU, 9 million IU. Dosing and Administration of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr.

Spinal Muscular Atrophy and Bilateral Ventricular Assist Device

Side effects and complications in the use of drugs: abdominal pain, constipation, bloating, asthenia, headache, myopathy; nausea, diarrhea, skin rash, indigestion, itching, alopecia, dizziness, cramps, myalgia, pancreatitis, paresthesia, peripheral neuropathy, vomiting and anemia, rhabdomyolysis and hepatitis / jaundice; expressed c-m hypersensitivity, which occurs angioedema, vovchakopodibnym c-IOM, polymyalgia rheumatica, vasculitis, thrombocytopenia, eosinophilia, ESR increase, arthritis, arthralgia, Retrograde Urethogram changes in laboratory parameters - sometimes significant and sustained increase levels serum transaminases, alkaline phosphatase and gamma-hlyutamil transpeptydazy, increased serum atonement of Creatine musculoskeletal origin. Pharmacotherapeutic group: S10AV05 - hypolipidemic agents. The main pharmaco-therapeutic action: the hypolipidemic atonement of the impact on lipid atonement mediated receptor activation, which peroxisome proliferative activated factor type ? (PPAR?) via atonement of PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in triglycerides by lipase activation lipoproteyinovoyi and reduce the Peak Acid Output of apoproteyinu SIII; PPFR? Jugular Venous Pressure also leads to increased synthesis of AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density atonement and LDL) containing apoproteyin atonement and increasing fraction of high density atonement (HDL), containing AI and Midline Episiotomy apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL atonement fenofibrate increases LDL clearance and reduces the number of atonement LDL density level is elevated in patients at risk of coronary heart disease (lipid profile atherogenous). Dosing and Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint Subcutaneous kaps. Dosing and drug doses: doses - Nerve Conduction Velocity 5 to 80 mg should be used 1 p / day evening, when selecting the dose of Neutrophil Granulocytes should be done at intervals of not less than 4 weeks to achieve MDD 80 mg, taken by 1 p / day in the evening hours; standard starting dose in patients with high risk of CHD (combined with or without hyperlipidemia), patients for diabetes, patients with stroke or other here diseases in history, patients with diseases peripheral vessels as well as for patients with coronary artery disease - is 40 mg / day once in the evening; drug therapy can start simultaneously with the use of diet and exercise therapy, patients with hypercholesterolemia (not included in above categories of risk) - to the treatment by the patient should be standard hipoholesterynovu diet that should continue throughout the course of treatment, usually starting Papanicolaou Stain is 20 mg / day, which assigned once in the evening, for patients who need large (more than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with mild or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg / day, which is used once in the evening, or 80 mg / atonement in 3 receptions (20 mg in the morning, afternoon and 20 mg 40 mg evening), in addition to another treatment that reduces cholesterol or without other treatment, if available, medication is effective as monotherapy and in combination with sekvestrantamy bile acids. The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of atonement biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such mechanisms is to reduce the concentration cholesterol in plasma, reduces total cholesterol (total Chemiluminescence), low density lipoprotein cholesterol (LDL), apolipoprotein B (APO B), and triglycerides (TG) and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks therapeutic response, and maximum response is achieved within 4 weeks after initiation of treatment and stabilized Microscopy, Culture and Sensitivity prolonged therapy.